Meta Pixel

News and Announcements

Announcing the Powerful Software Driven Future of Capital Raising

  • Published November 24, 2019 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Capital Insights

Every year Billions of dollars are invested into technologies that have transformed the way watch content, order transport, listen to music, and book accommodation. Netflix, UBER, Spotify, and Airbnb.

The goal of this investment is for software and data to remove friction from connecting consumers and their desired outcomes/experience.

In a B2B environment, this is also the case. SaaS Platforms have transformed the way companies engage with software. In a survey conducted by BetterCloud, 73% of organizations who responded said that at least 80% of their apps would be SaaS by 2020. 

The survey highlights that when companies are looking at purchasing SaaS solutions, their criteria centers around cost, security, ease of use, integrations, scalability, reporting, and analytics.

The question which drives our thinking is, how can we utilise software to remove friction from the private capital raising process, to save time and money while also improving access to investors, efficiency, and analytics?

Current Private Capital Raising Experience

Currently, you have the process focused around personal networks, legacy systems, isolated solutions, manual processes, virtually no deal analytics, lack of investor connectivity, and a fragmented ecosystem with minimal co-operation and online platforms charging 6 to 8% and competing with the professional service firms.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now